Image-Guided Versus Conventional Brachytherapy for Locally Advanced Cervical Cancer: Experience of Single Institution with the Same Practitioner and Time Period

Purpose This study aimed to compare treatment outcomes and toxicity profile between imaged-guided brachytherapy (IGBT) versus conventional brachytherapy (CBT) performed by the same practitioner during the same time period.Materials and Methods Medical records of 104 eligible patients who underwent b...

Full description

Saved in:
Bibliographic Details
Published inCancer research and treatment Vol. 55; no. 1; pp. 258 - 269
Main Authors Lee, Tae Hoon, Kim, Kyung Su, Kim, Hak Jae, Choi, Chang Heon, Kang, Seonghee, Eom, Keun-Yong, Wee, Chan Woo, Song, Yong Sang, Park, Noh Hyun, Kim, Jae-Weon, Chung, Hyun Hoon, Kim, Hee Seung, Lee, Maria, Kang, Hyun-Cheol
Format Journal Article
LanguageEnglish
Published Korea (South) Korean Cancer Association 01.01.2023
대한암학회
Subjects
Online AccessGet full text
ISSN1598-2998
2005-9256
2005-9256
DOI10.4143/crt.2022.418

Cover

Abstract Purpose This study aimed to compare treatment outcomes and toxicity profile between imaged-guided brachytherapy (IGBT) versus conventional brachytherapy (CBT) performed by the same practitioner during the same time period.Materials and Methods Medical records of 104 eligible patients who underwent brachytherapy for locally advanced cervical cancer were retrospectively reviewed. Fifty patients (48.1%) underwent IGBT, and 54 (51.9%) patients underwent CBT. All patients underwent concurrent chemoradiation with cisplatin. High-dose-rate intracavitary brachytherapy with dose prescription of 25-30 Gy in 4-6 fractions was performed for all patients. Late lower gastrointestinal (GI) and urinary toxicities occurred more than 3 months after the end of brachytherapy were included for comparative and dosimetric analyses.Results The median follow-up period was 18.33 months (range, 3.25 to 38.43 months). There were no differences in oncologic outcomes between the two groups. The IGBT group had lower rate of actuarial grade ≥ 3 toxicity than the CBT group (2-year, 4.5% vs. 25.7%; p=0.030). Cumulative equieffective D2cc of sigmoid colon was significantly correlated with grade ≥ 2 lower GI toxicity (p=0.033), while equieffective D2cc of rectum (p=0.055) and bladder (p=0.069) showed marginal significance with corresponding grade ≥ 2 toxicities in the IGBT group. Half of grade ≥ 3 lower GI toxicities impacted GI tract above the rectum. Optimal thresholds of cumulative D2cc of sigmoid colon and rectum were 69.7 Gy and 70.8 Gy, respectively, for grade ≥ 2 lower GI toxicity.Conclusion IGBT showed superior toxicity profile to CBT. Evaluating the dose to the GI tract above rectum by IGBT might prevent some toxicities.
AbstractList Purpose This study aimed to compare treatment outcomes and toxicity profile between imaged-guided brachytherapy (IGBT) versus conventional brachytherapy (CBT) performed by the same practitioner during the same time period.Materials and Methods Medical records of 104 eligible patients who underwent brachytherapy for locally advanced cervical cancer were retrospectively reviewed. Fifty patients (48.1%) underwent IGBT, and 54 (51.9%) patients underwent CBT. All patients underwent concurrent chemoradiation with cisplatin. High-dose-rate intracavitary brachytherapy with dose prescription of 25-30 Gy in 4-6 fractions was performed for all patients. Late lower gastrointestinal (GI) and urinary toxicities occurred more than 3 months after the end of brachytherapy were included for comparative and dosimetric analyses.Results The median follow-up period was 18.33 months (range, 3.25 to 38.43 months). There were no differences in oncologic outcomes between the two groups. The IGBT group had lower rate of actuarial grade ≥ 3 toxicity than the CBT group (2-year, 4.5% vs. 25.7%; p=0.030). Cumulative equieffective D2cc of sigmoid colon was significantly correlated with grade ≥ 2 lower GI toxicity (p=0.033), while equieffective D2cc of rectum (p=0.055) and bladder (p=0.069) showed marginal significance with corresponding grade ≥ 2 toxicities in the IGBT group. Half of grade ≥ 3 lower GI toxicities impacted GI tract above the rectum. Optimal thresholds of cumulative D2cc of sigmoid colon and rectum were 69.7 Gy and 70.8 Gy, respectively, for grade ≥ 2 lower GI toxicity.Conclusion IGBT showed superior toxicity profile to CBT. Evaluating the dose to the GI tract above rectum by IGBT might prevent some toxicities. KCI Citation Count: 0
This study aimed to compare treatment outcomes and toxicity profile between imaged-guided brachytherapy (IGBT) versus conventional brachytherapy (CBT) performed by the same practitioner during the same time period.PURPOSEThis study aimed to compare treatment outcomes and toxicity profile between imaged-guided brachytherapy (IGBT) versus conventional brachytherapy (CBT) performed by the same practitioner during the same time period.Medical records of 104 eligible patients who underwent brachytherapy for locally advanced cervical cancer were retrospectively reviewed. Fifty patients (48.1%) underwent IGBT, and 54 (51.9%) patients underwent CBT. All patients underwent concurrent chemoradiation with cisplatin. High-dose-rate intracavitary brachytherapy with dose prescription of 25-30 Gy in 4-6 fractions was performed for all patients. Late lower gastrointestinal (GI) and urinary toxicities occurred more than 3 months after the end of brachytherapy were included for comparative and dosimetric analyses.MATERIALS AND METHODSMedical records of 104 eligible patients who underwent brachytherapy for locally advanced cervical cancer were retrospectively reviewed. Fifty patients (48.1%) underwent IGBT, and 54 (51.9%) patients underwent CBT. All patients underwent concurrent chemoradiation with cisplatin. High-dose-rate intracavitary brachytherapy with dose prescription of 25-30 Gy in 4-6 fractions was performed for all patients. Late lower gastrointestinal (GI) and urinary toxicities occurred more than 3 months after the end of brachytherapy were included for comparative and dosimetric analyses.The median follow-up period was 18.33 months (range, 3.25 to 38.43 months). There were no differences in oncologic outcomes between the two groups. The IGBT group had lower rate of actuarial grade ≥ 3 toxicity than the CBT group (2-year, 4.5% vs. 25.7%; p=0.030). Cumulative equieffective D2cc of sigmoid colon was significantly correlated with grade ≥ 2 lower GI toxicity (p=0.033), while equieffective D2cc of rectum (p=0.055) and bladder (p=0.069) showed marginal significance with corresponding grade ≥ 2 toxicities in the IGBT group. Half of grade ≥ 3 lower GI toxicities impacted GI tract above the rectum. Optimal thresholds of cumulative D2cc of sigmoid colon and rectum were 69.7 Gy and 70.8 Gy, respectively, for grade ≥ 2 lower GI toxicity.RESULTSThe median follow-up period was 18.33 months (range, 3.25 to 38.43 months). There were no differences in oncologic outcomes between the two groups. The IGBT group had lower rate of actuarial grade ≥ 3 toxicity than the CBT group (2-year, 4.5% vs. 25.7%; p=0.030). Cumulative equieffective D2cc of sigmoid colon was significantly correlated with grade ≥ 2 lower GI toxicity (p=0.033), while equieffective D2cc of rectum (p=0.055) and bladder (p=0.069) showed marginal significance with corresponding grade ≥ 2 toxicities in the IGBT group. Half of grade ≥ 3 lower GI toxicities impacted GI tract above the rectum. Optimal thresholds of cumulative D2cc of sigmoid colon and rectum were 69.7 Gy and 70.8 Gy, respectively, for grade ≥ 2 lower GI toxicity.IGBT showed superior toxicity profile to CBT. Evaluating the dose to the GI tract above rectum by IGBT might prevent some toxicities.CONCLUSIONIGBT showed superior toxicity profile to CBT. Evaluating the dose to the GI tract above rectum by IGBT might prevent some toxicities.
This study aimed to compare treatment outcomes and toxicity profile between imaged-guided brachytherapy (IGBT) versus conventional brachytherapy (CBT) performed by the same practitioner during the same time period. Medical records of 104 eligible patients who underwent brachytherapy for locally advanced cervical cancer were retrospectively reviewed. Fifty patients (48.1%) underwent IGBT, and 54 (51.9%) patients underwent CBT. All patients underwent concurrent chemoradiation with cisplatin. High-dose-rate intracavitary brachytherapy with dose prescription of 25-30 Gy in 4-6 fractions was performed for all patients. Late lower gastrointestinal (GI) and urinary toxicities occurred more than 3 months after the end of brachytherapy were included for comparative and dosimetric analyses. The median follow-up period was 18.33 months (range, 3.25 to 38.43 months). There were no differences in oncologic outcomes between the two groups. The IGBT group had lower rate of actuarial grade ≥ 3 toxicity than the CBT group (2-year, 4.5% vs. 25.7%; p=0.030). Cumulative equieffective D2cc of sigmoid colon was significantly correlated with grade ≥ 2 lower GI toxicity (p=0.033), while equieffective D2cc of rectum (p=0.055) and bladder (p=0.069) showed marginal significance with corresponding grade ≥ 2 toxicities in the IGBT group. Half of grade ≥ 3 lower GI toxicities impacted GI tract above the rectum. Optimal thresholds of cumulative D2cc of sigmoid colon and rectum were 69.7 Gy and 70.8 Gy, respectively, for grade ≥ 2 lower GI toxicity. IGBT showed superior toxicity profile to CBT. Evaluating the dose to the GI tract above rectum by IGBT might prevent some toxicities.
Purpose This study aimed to compare treatment outcomes and toxicity profile between imaged-guided brachytherapy (IGBT) versus conventional brachytherapy (CBT) performed by the same practitioner during the same time period.Materials and Methods Medical records of 104 eligible patients who underwent brachytherapy for locally advanced cervical cancer were retrospectively reviewed. Fifty patients (48.1%) underwent IGBT, and 54 (51.9%) patients underwent CBT. All patients underwent concurrent chemoradiation with cisplatin. High-dose-rate intracavitary brachytherapy with dose prescription of 25-30 Gy in 4-6 fractions was performed for all patients. Late lower gastrointestinal (GI) and urinary toxicities occurred more than 3 months after the end of brachytherapy were included for comparative and dosimetric analyses.Results The median follow-up period was 18.33 months (range, 3.25 to 38.43 months). There were no differences in oncologic outcomes between the two groups. The IGBT group had lower rate of actuarial grade ≥ 3 toxicity than the CBT group (2-year, 4.5% vs. 25.7%; p=0.030). Cumulative equieffective D2cc of sigmoid colon was significantly correlated with grade ≥ 2 lower GI toxicity (p=0.033), while equieffective D2cc of rectum (p=0.055) and bladder (p=0.069) showed marginal significance with corresponding grade ≥ 2 toxicities in the IGBT group. Half of grade ≥ 3 lower GI toxicities impacted GI tract above the rectum. Optimal thresholds of cumulative D2cc of sigmoid colon and rectum were 69.7 Gy and 70.8 Gy, respectively, for grade ≥ 2 lower GI toxicity.Conclusion IGBT showed superior toxicity profile to CBT. Evaluating the dose to the GI tract above rectum by IGBT might prevent some toxicities.
Author Park, Noh Hyun
Lee, Maria
Lee, Tae Hoon
Chung, Hyun Hoon
Kang, Seonghee
Kim, Jae-Weon
Wee, Chan Woo
Song, Yong Sang
Kang, Hyun-Cheol
Kim, Hak Jae
Kim, Kyung Su
Choi, Chang Heon
Kim, Hee Seung
Eom, Keun-Yong
AuthorAffiliation 2 Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea
4 Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, Korea
1 Department of Radiation Oncology, Seoul National University Hospital, Seoul, Korea
3 Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
6 Department of Radiation Oncology, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea
7 Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Korea
5 Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, Korea
AuthorAffiliation_xml – name: 3 Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea
– name: 4 Institute of Radiation Medicine, Seoul National University College of Medicine, Seoul, Korea
– name: 5 Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, Korea
– name: 2 Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea
– name: 6 Department of Radiation Oncology, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea
– name: 1 Department of Radiation Oncology, Seoul National University Hospital, Seoul, Korea
– name: 7 Department of Obstetrics and Gynecology, Seoul National University Hospital, Seoul, Korea
Author_xml – sequence: 1
  givenname: Tae Hoon
  surname: Lee
  fullname: Lee, Tae Hoon
– sequence: 2
  givenname: Kyung Su
  surname: Kim
  fullname: Kim, Kyung Su
– sequence: 3
  givenname: Hak Jae
  surname: Kim
  fullname: Kim, Hak Jae
– sequence: 4
  givenname: Chang Heon
  surname: Choi
  fullname: Choi, Chang Heon
– sequence: 5
  givenname: Seonghee
  surname: Kang
  fullname: Kang, Seonghee
– sequence: 6
  givenname: Keun-Yong
  surname: Eom
  fullname: Eom, Keun-Yong
– sequence: 7
  givenname: Chan Woo
  surname: Wee
  fullname: Wee, Chan Woo
– sequence: 8
  givenname: Yong Sang
  surname: Song
  fullname: Song, Yong Sang
– sequence: 9
  givenname: Noh Hyun
  surname: Park
  fullname: Park, Noh Hyun
– sequence: 10
  givenname: Jae-Weon
  surname: Kim
  fullname: Kim, Jae-Weon
– sequence: 11
  givenname: Hyun Hoon
  surname: Chung
  fullname: Chung, Hyun Hoon
– sequence: 12
  givenname: Hee Seung
  surname: Kim
  fullname: Kim, Hee Seung
– sequence: 13
  givenname: Maria
  surname: Lee
  fullname: Lee, Maria
– sequence: 14
  givenname: Hyun-Cheol
  surname: Kang
  fullname: Kang, Hyun-Cheol
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35952716$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002923313$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNptUktvEzEQtlARTQs3zshHhNiy9r5sDkhhVUqkSCAauFqOH4nprh3s3UD-DT-V2aZFgDiNPs_3GI3nDJ344A1CT0l-UZKyeKXicEFzSgGxB2hG87zKOK3qEzQjFWcZ5ZydorOUvuZ5XRYNeYROi4pXtCH1DP1c9HJjsqvRaaPxFxPTmHAb_N74wQUvO_w2SrU9DFsT5e6AbYh4GZTsugOe6730CmStiXsHb7idcHyNL3_sTHQGAA4WXzu_6Qxe-DS4YZxs8Xc3bDF44mvZG_wRIqAFDROx9Bqv3PQKFkE_Rg-t7JJ5clfP0ed3l6v2fbb8cLVo58tMlYQPWWM5LyorK6Z1RbnUNaW0oQWz1JCyYUxLu7YVKUtO6pzkimtty9LytdJrzeviHL04-vpoxY1yIkh3WzdB3EQx_7RaCALChhIC5DdH8m5c90YrWFaUndhF18t4uJX-3fFuC0Z7wVlTFJSBwfM7gxi-jSYNondJma6T3oQxCdrklLCmptNgz_7M-h1y_4dAoEeCiiGlaKxQbpDTNiHadTC1mA5FwKGI6VAATQO8_Ed07_tf-i_338Jk
CitedBy_id crossref_primary_10_1007_s40278_023_35265_1
crossref_primary_10_3390_healthcare11152187
Cites_doi 10.3802/jgo.2016.27.e33
10.1016/j.ygyno.2020.03.006
10.1016/j.radonc.2009.06.032
10.5114/jcb.2018.73955
10.1016/j.radonc.2011.08.014
10.1016/j.radonc.2016.06.006
10.1016/j.brachy.2017.05.001
10.3109/0284186x.2013.818253
10.1016/j.radonc.2021.01.019
10.1016/j.brachy.2018.04.005
10.1016/j.ygyno.2014.08.027
10.1136/ijgc-2019-001135
10.1016/j.radonc.2004.12.015
10.1093/jrr/rrv047
10.1016/j.brachy.2021.03.004
10.1016/j.ijrobp.2013.05.033
10.1007/s00066-020-01658-0
10.1016/j.ijrobp.2010.12.029
10.1186/s13014-021-01877-4
10.1016/j.brachy.2011.07.002
10.1097/igc.0000000000000883
10.1016/j.ijrobp.2009.10.075
10.1016/j.ygyno.2015.02.025
10.3346/jkms.2018.33.e135
10.1016/j.radonc.2016.03.011
10.1016/j.ijrobp.2018.11.012
10.1016/s0167-8140(03)00189-0
10.1016/s1470-2045(12)70011-6
ContentType Journal Article
Copyright Copyright © 2023 by the Korean Cancer Association 2023
Copyright_xml – notice: Copyright © 2023 by the Korean Cancer Association 2023
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ACYCR
DOI 10.4143/crt.2022.418
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Korean Citation Index
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2005-9256
EndPage 269
ExternalDocumentID oai_kci_go_kr_ARTI_10107211
PMC9873328
35952716
10_4143_crt_2022_418
Genre Journal Article
GroupedDBID ---
29B
5-W
53G
8JR
9ZL
AAYXX
ABDBF
ACUHS
ACYCR
ADBBV
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
DIK
E3Z
EBD
EF.
F5P
HYE
OK1
RPM
TR2
C1A
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
M~E
ID FETCH-LOGICAL-c419t-7f9935fa58dd529ad62227238f2e14788dafbf5144916010c9ddf44f9bcdbd963
ISSN 1598-2998
2005-9256
IngestDate Sat Apr 06 03:24:31 EDT 2024
Thu Aug 21 18:38:13 EDT 2025
Thu Jul 10 22:46:09 EDT 2025
Thu Apr 03 07:09:56 EDT 2025
Thu Apr 24 23:10:15 EDT 2025
Tue Jul 01 03:18:51 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Uterine cervical neoplasms
Brachytherapy
Sigmoid colon
Three-dimensional imaging
Rectum
Language English
License This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c419t-7f9935fa58dd529ad62227238f2e14788dafbf5144916010c9ddf44f9bcdbd963
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-8981-6123
0000-0002-4723-3931
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC9873328
PMID 35952716
PQID 2702187626
PQPubID 23479
PageCount 12
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_10107211
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9873328
proquest_miscellaneous_2702187626
pubmed_primary_35952716
crossref_citationtrail_10_4143_crt_2022_418
crossref_primary_10_4143_crt_2022_418
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-01-01
PublicationDateYYYYMMDD 2023-01-01
PublicationDate_xml – month: 01
  year: 2023
  text: 2023-01-01
  day: 01
PublicationDecade 2020
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle Cancer research and treatment
PublicationTitleAlternate Cancer Res Treat
PublicationYear 2023
Publisher Korean Cancer Association
대한암학회
Publisher_xml – name: Korean Cancer Association
– name: 대한암학회
References ref12
ref14
ref31
ref11
ref10
ref32
ref2
ref1
ref17
ref16
ref19
ref18
(ref13) 1985
Kemp (ref30) c2022
ref24
ref23
ref26
ref25
Potter (ref4) 2021
ref20
ref22
ref21
ref28
ref27
(ref15) c2017
ref29
ref8
ref7
ref9
ref3
ref6
ref5
References_xml – ident: ref6
  doi: 10.3802/jgo.2016.27.e33
– start-page: 538
  volume-title: MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study
  year: 2021
  ident: ref4
– ident: ref32
  doi: 10.1016/j.ygyno.2020.03.006
– ident: ref26
  doi: 10.1016/j.radonc.2009.06.032
– ident: ref10
  doi: 10.5114/jcb.2018.73955
– ident: ref31
  doi: 10.1016/j.radonc.2011.08.014
– ident: ref22
  doi: 10.1016/j.radonc.2016.06.006
– volume-title: Update on CALLA Phase III trial of concurrent use of Imfinzi and chemoradiotherapy in locally advanced cervical cancer [Internet]
  year: c2022
  ident: ref30
– ident: ref9
  doi: 10.1016/j.brachy.2017.05.001
– ident: ref18
  doi: 10.3109/0284186x.2013.818253
– ident: ref24
  doi: 10.1016/j.radonc.2021.01.019
– ident: ref27
  doi: 10.1016/j.brachy.2018.04.005
– ident: ref8
  doi: 10.1016/j.ygyno.2014.08.027
– volume-title: Dose and volume specification for reporting intracavitary therapy in gynaecology
  year: 1985
  ident: ref13
– ident: ref12
  doi: 10.1136/ijgc-2019-001135
– ident: ref14
  doi: 10.1016/j.radonc.2004.12.015
– ident: ref5
  doi: 10.1093/jrr/rrv047
– ident: ref17
  doi: 10.1016/j.brachy.2021.03.004
– ident: ref1
  doi: 10.1016/j.ijrobp.2013.05.033
– ident: ref16
  doi: 10.1007/s00066-020-01658-0
– ident: ref23
  doi: 10.1016/j.ijrobp.2010.12.029
– ident: ref2
  doi: 10.1186/s13014-021-01877-4
– ident: ref21
  doi: 10.1016/j.brachy.2011.07.002
– ident: ref28
  doi: 10.1097/igc.0000000000000883
– ident: ref11
  doi: 10.1016/j.ijrobp.2009.10.075
– ident: ref3
  doi: 10.1016/j.ygyno.2015.02.025
– ident: ref7
  doi: 10.3346/jkms.2018.33.e135
– ident: ref20
  doi: 10.1016/j.radonc.2016.03.011
– volume-title: Common Terminology Criteria for Adverse Events (CTCAE) v5.0 [Internet]
  year: c2017
  ident: ref15
– ident: ref19
  doi: 10.1016/j.ijrobp.2018.11.012
– ident: ref25
  doi: 10.1016/s0167-8140(03)00189-0
– ident: ref29
  doi: 10.1016/s1470-2045(12)70011-6
SSID ssj0064371
Score 2.264786
Snippet Purpose This study aimed to compare treatment outcomes and toxicity profile between imaged-guided brachytherapy (IGBT) versus conventional brachytherapy (CBT)...
This study aimed to compare treatment outcomes and toxicity profile between imaged-guided brachytherapy (IGBT) versus conventional brachytherapy (CBT)...
SourceID nrf
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 258
SubjectTerms Brachytherapy - adverse effects
Female
Gastrointestinal Diseases - etiology
Humans
Original
Radiotherapy Dosage
Rectum
Retrospective Studies
Uterine Cervical Neoplasms - drug therapy
Uterine Cervical Neoplasms - radiotherapy
의학일반
Title Image-Guided Versus Conventional Brachytherapy for Locally Advanced Cervical Cancer: Experience of Single Institution with the Same Practitioner and Time Period
URI https://www.ncbi.nlm.nih.gov/pubmed/35952716
https://www.proquest.com/docview/2702187626
https://pubmed.ncbi.nlm.nih.gov/PMC9873328
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART002923313
Volume 55
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Cancer Research and Treatment, 2023, 55(1), , pp.258-269
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLa6TZr2griv3GQEPFWB2kmamre2MLrBeGGT9hYljk2rXjKV5qH8Gh75mZxjO2lSbRLwktaJa0s9X-xj-zvfIeS1FNL3BePwirPEC5gWXp9HGAUcZjzlXSFNFoXzr73xZXB2FV61Wr9rrKVinb6VP2-MK_kfq8I9sCtGyf6DZatG4QZ8B_vCFSwM17-y8ekCRgPvUzHNwG3Ena_CZODc0siHq0RONjbGyjIzv-DcNd90BuXZ_8gMFriFgGWTNHIrf2xCWmBym6uKVYBwsZu3ALBvyUI1JI_MWQSGlSC1fpo3soDaDjpOXshG1FU89x1i0EWiOuO8ThEwuP28KVBAvNi5PU5mnbOkguhokk8dlQBqj5Vrxu1tcL-2t6HMGGiEUgW32uPlgG11fRvAdKOvVYHfnRUC8AnBlHKF3FnOodyoBn_s9cIgBIOUecR2pLntZO8e7ZEDHkVICDgYDD8MT8pZH88_mQ2swO7e1Ts7Ioflzxvez95ypW9a2Ozyc2sOz8VdcsetVOjAwu4eaanlfXJ47rgYD8ivOvqoRR-to4820EcBfdShj5booyX6qAXHe7rFHs01tdijNexRxB6FNilij9axRwFQFLFHLfYeksuTjxejsefyfXgyYGLtRRqc5VAnYT_LQi6SrIeB2uBTaq4YpnnIEp1q8PADWNN0WVeKLNNBoEUqszSDmeQR2V9Cf8eEMulH2lc-ih0F3UilIk2QYyFCIWWgZZt0SjvE0onhY06WeQyLYjRgDAaM0YBQ6rfJm6r2tRWBuaXeKzBpPJPTGFXb8fN7Hs9WMaxNT5FMiWKErE1eliaPYSzHA7pkqfLiR4yxoQzdk16bPLYQqPorEdQmUQMcVQXssflkOZ0YvXjRj3yf95_c2uZTcrR9-56R_fWqUM_B116nLxzM_wAv3NnD
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Image-Guided+Versus+Conventional+Brachytherapy+for+Locally+Advanced+Cervical+Cancer%3A+Experience+of+Single+Institution+with+the+Same+Practitioner+and+Time+Period&rft.jtitle=Cancer+research+and+treatment&rft.au=Lee%2C+Tae+Hoon&rft.au=Kim%2C+Kyung+Su&rft.au=Kim%2C+Hak+Jae&rft.au=Choi%2C+Chang+Heon&rft.date=2023-01-01&rft.eissn=2005-9256&rft.volume=55&rft.issue=1&rft.spage=258&rft_id=info:doi/10.4143%2Fcrt.2022.418&rft_id=info%3Apmid%2F35952716&rft.externalDocID=35952716
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1598-2998&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1598-2998&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1598-2998&client=summon